Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant should be healthy on the basis of physical examination, medical history, vital signs, and electrocardiogram and clinical laboratory tests performed at screening~* Have a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.5 to 30.0 kg/m2, extremes included~* Men and women must agree to use a highly effective method of birth control~Exclusion Criteria:~* Has a positive HIV-1 or HIV-2 test at screening~* Has a Hepatitis A, B or C infection (confirmed by hepatitis A antibody immunoglobulin M (IgM), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody, respectively) at screening~* Has any history of renal insufficiency~* Has a history of significant skin reactions or any history of allergies to drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
- Treatment B (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
- Treatment C (Type: EXPERIMENTAL): Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
- Treatment D (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
- Treatment E (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
- Treatment F (Type: EXPERIMENTAL): Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).

Based on this trial design, predict the completion outcome and termination type (if applicable).